secwatch.observer — SEC 8-K summary
======================================

Issuer:     HYPERION DEFI, INC. (HYPD)
CIK:        0001682639
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001104659-23-039153
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eyenovia reports FY2022 net loss $28.0M; Mydcombi PDUFA date May 8, 2023
------------------------------------------------------------------------

- Net loss $28.0M ($0.83/share) for FY2022 vs $12.8M loss in FY2021; Q4 loss $6.1M.
- Cash and equivalents $22.9M at Dec 31, 2022, down from $27.3M at Dec 31, 2021.
- FDA accepted Mydcombi NDA; PDUFA action target date May 8, 2023.
- Positive Phase 3 results for Microline (presbyopia); FDA feedback outlines clear path forward.
- Co-development agreement with Formosa Pharmaceuticals to combine Optejet with APNT nanoparticle platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682639/000110465923039153/0001104659-23-039153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682639/000110465923039153/tm2311016d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-039153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer